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Introduction. Matrix metalloproteinase (MMP) is an emerging disease marker in rheumatic diseases. This is a meta-analysis aimed
at systematically reviewing association between serumMMP-3 levels and systematic lupus erythematosus (SLE) activity, which sought
to raise interest in MMP-3 as a putative biomarker.Methods. We conducted a meta-analysis of serum MMP-3 levels in patients with
SLE and controls. We performed a PubMed search, EMBASE search, and forward search of the retrieved articles published until Oct.
1, 2018. In addition to this, we included data from a case-control study on a national pediatric SLE cohort, in which serum MMP-3
levels were measured in 11 SLE patients and 9 controls (unpublished). Subgroup analyses based on gender and disease activity were
performed. Results. A total of 662 cases and 771 controls including 651 patients and 762 controls from 11 publications were studied.
We observed signiﬁcantly higher MMP-3 levels in SLE patients compared to healthy controls (P < 0 001, Hedges’ g: 2.104, 95% CI
1.426-2.782). In subgroup analyses, we found a signiﬁcant elevation of MMP-3 in the patients with nephritis compared to those
without (P = 0 006, Hedges’ g: 0.611, 95% CI 0.611-1.704). This ﬁnding was consistent between patients with persistent proteinuria
and those without (P = 0 023, Hedges’ g: 1.535, 95% CI 0.207-2.862). Meta-analysis showed no association between MMP-3 levels
and gender or anti-double strand DNA antibody titer. Conclusions. Our meta-analysis demonstrated signiﬁcantly higher MMP-3
levels in SLE patients than in controls and in patients with renal involvement than in those without.
1. Introduction
Systemic lupus erythematosus (SLE) is a multisystemic
autoimmune disease [1]. Although the pathogenesis of SLE
remains yet to be elucidated, studies have reported its
association with dysregulation of matrix metalloproteinases
(MMPs) [2, 3]. MMPs, a family of enzymes, were discovered
for the ability to degrade extracellular matrix (ECM) and
basement membrane components [4]. Since they have
important roles in wound healing through processes
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implicated in tissue remodeling [4, 5], an imbalance between
MMPs and their endogenous inhibitors, such as tissue inhib-
itors of metalloproteinases (TIMPs), may lead to tissue
destruction and associated inﬂammatory diseases [4, 5].
A body of literature investigated MMP as a potential bio-
marker in various rheumatic diseases, namely, rheumatoid
arthritis, Kawasaki disease, giant cell arteritis, Takayasu
arteritis, and anti-neutrophil cytoplasmic antibody (ANCA)
-associatedvasculitis [6–10]. In addition, our group has pre-
viously studied the expression proﬁles of all known MMPs
and TIMPs in children with IgA vasculitis (former Henoch-
Schönlein purpura (HSP)) [11]. Increased levels of MMPs
and TIMPs in children with IgA vasculitis were observed
[11]. In patients with SLE, MMPs including MMP-2, 3, 9,
and 13 are proposed to correlate with SLE activity [2, 3, 12,
13]. However, conﬂicting data on serum MMP-3 levels and
its correlation with SLE [2, 3, 12] prompted us to further
investigate its role.
We performed this meta-analysis to review serum
MMP-3 levels in patients with SLE compared to those in
healthy controls and determine the correlation of MMP-3
levels with disease activity of SLE.
2. Methods
2.1. Search Strategy and Data Extraction. We performed a
PubMed, EMBASE, and Google Scholar search to identify
eligible articles. Furthermore, a forward search of the
retrieved articles was performed, and “Google Scholar” was
assessed to screen fornonindexedpublications. The last search
in EMBASE and PubMed was performed onOct. 1, 2018. The
search terms included the following: systemic lupus erythema-
tosusOR “SLE”OR “lupus”OR “lupus nephritis”ANDmatrix
metalloproteinase 3 OR “matrix metalloproteinase-3” OR
“MMP 3” OR “MMP-3” OR “Stromelysin 1” OR
“Stromelysin-1”. The detailed search strategy is as follows.
PubMed and MEDLINE search strategy (last search
performed on Oct. 1, 2018):
#1 “systemic lupus erythematosus” [All Fields] or
[Mesh]
#2 “lupus nephritis” [All Fields]
#3 “lupus” [All Fields]
#4 #1 OR #2 OR #3
#5 “matrix metalloproteinase 3” [All Fields] or [Mesh]
#6 “matrix metalloprotease-3” [All Fields]
#7 “MMP 3” [All Fields] OR “MMP-3” [All Fields]
#8 “Stromelysin 1” [All Fields] OR “Stromelysin-1” [All
Fields]
#9 #5 OR #6 OR #7 OR #8
#10 #4 AND #9
We examined and screened the articles ﬁrstly by titles,
followed by abstracts, and eventually by assessing and read-
ing the respective full texts. The detailed process of reviewing
the articles is presented in Figure 1.
2.2. Eligibility Criteria. We included cross-sectional or longi-
tudinal studies which measured MMP-3 levels in the sera of
patients with SLE and compared them with controls. We
excluded studies that measured MMP-3 in the joint ﬂuid or
kidney tissues. Animal studies were also excluded. The deci-
sion to include or exclude was made independently by two
authors (Lee JM and Shin JI), and any disagreements were
settled by discussion.
2.3. Quality Assessment. The meta-analysis followed the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement (Supplementary Table S1). We
used the Newcastle-Ottawa Scale (NOS) [14] to score the
quality of the studies, recommended by the Cochrane
Collaboration [14]. The scoring was performed independently
by two researchers (Shin JI and Lee JM). The NOS ranges
from 0 to 9 stars; a study can be awarded a maximum of
one star for each numbered item within the Selection and
Exposure categories. A maximum of two stars can be given
for comparability. If more than 6 stars were given, the
study is assumed to have a high quality (Supplementary
Table S2).
2.4. Unpublished Data from Pediatric SLE Cohort. In order to
reinforce the power of the meta-analysis, we included our
data from a case-control study, which we performed earlier
on the national pediatric SLE cohort (KPS) (data not pub-
lished). We were able to quantify serum MMP-3 levels in
11 children with SLE and 9 healthy controls. Detailed
information with regard to this cross-sectional study is
provided as Supplementary Materials and in Supplementary
Table S3.
2.5. Statistical Analysis and Evaluation of Heterogeneity and
Publication Bias. We calculated Hedges’ g, and correspond-
ing 95% conﬁdence intervals (CIs) were used to compare
serum MMP-3 levels. All meta-analyses were performed
using random and ﬁxed eﬀects models, but only random
eﬀects models were used because true diﬀerences among
the studies were expected due to heterogeneity.
We assessed the heterogeneity of the studies by using the
CochranQ test, and a P value of < 0.05 was considered signif-
icant. The inconsistency across the studies was also measured
by I2 metric, as a measure of the percentage of total variation
across the studies because of heterogeneity. I2 values of <25,
25-75, and >75% were considered to represent low, moder-
ate, and high levels of heterogeneity, respectively. Publication
bias of each article was estimated by inspecting a funnel plot
and using the Egger test. All analyses were conducted using
Comprehensive Meta-Analysis v.2.0 (Biostat, Englewood,
NJ, USA).
3. Results
3.1. Study Selection and Characteristics. We were able to
identify 202 articles using electronic and manual researches.
After reviewing titles and abstracts, 31 studies were selected
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for full-text reading. Of them, 17 were excluded due to
duplicates, irrelevance, or inappropriateness. Of the remain-
ing 14 studies, 3 were excluded (2 lacked numerical ﬁgures,
and 1 did not report MMP-3 levels in controls) to ﬁnally
include 11 eligible articles (Figure 1) [2, 3, 12, 15–22]. Here,
we included results from a national pediatric SLE cohort
(KPS) involving 11 SLE and 9 healthy controls.
The respective characteristics of included studies are
summarized in Table 1. The PRISMA checklist for meta-
analyses is shown in Supplementary Table S1. Study quality
assessed by using the Newcastle-Ottawa scale (NOS) scored
6 in two studies, 7 in three studies, and 8 in four studies
(range: 1 (very poor) to 9 (very high); Supplementary
Table S2).
3.2. Meta-analysis of MMP-3 Levels in SLE Patients
Compared to Controls. A meta-analysis on SLE patients and
healthy controls was performed. Extracting data from 12
studies (11 published articles and KPS data), there were 662
patients with SLE and 771 controls. The results revealed that
MMP-3 levels were signiﬁcantly higher in the SLE group
than in the control group (P < 0 001, Hedges’ g: 2.104, 95%
CI 1.426-2.782) (Table 2 and Figure 2). We then performed
the same analysis excluding our KPS data to conﬁrm that
the results were not aﬀected by including pediatric data.
The results consistently showed that MMP-3 levels were
signiﬁcantly higher in SLE patients than in controls
(P = 0 001, Hedges’ g: 1.963, 95% CI 1.276-2.650) (Table 2
and Figure 3).
77 articles reviewed by abstract screening
44 articles were excluded
11 were not about MMP-3
8 were genetic studies
7 were reviews
4 were not related to SLE
4 were animal studies
4 were about pathophysiology
3 were immunohistochemistry studies
2 were about treatment
1 was about clinical manifestations
1 was a case report
1 was a duplicate  
202 articles reviewed by title screening
125 articles were excluded
110 were duplicates
7 were not related to SLE
2 were not about MMP-3
2 were genetic studies
1 was about treatment
1 was an animal study
1 was a review
1 was a meeting report 
1 did not report the MMP-3
levels in the controls    
31 articles were selected for full-text search
17 articles were excluded
5 were reviews
4 were not about MMP-3
4 were abstracts of congress
2 were not about lupus
1 was an introduction only
1 was a meeting report 
11 eligible articles were included in the meta-
analysis related to SLE and MMP-3 published until
Oct. 1, 2018 
2 lacked numerical figures
Figure 1: Flow diagram of search strategy.
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3.3. Meta-analysis of MMP-3 Levels in Subgroups by Gender.
In subgroup analyses, we ﬁrstly compared serum MMP-3
levels in male vs. female SLE patients. Data were extracted
from two studies; Ichikawa et al. [18] and KPS (unpublished).
The results revealed no signiﬁcant diﬀerence (P = 0 407,
Hedges’ g: 0.360, 95% CI -0.491-1.212) (Figure 4).
3.4. Meta-analysis of MMP-3 Levels in SLE Patients with
Renal Involvement and Those Without.We compared serum
MMP-3 levels in SLE patients with active nephritis (n = 53)
and those without (n = 39). Data were extracted from three
studies. Kotajima et al. [2] deﬁned active nephritis according
to the SLEDAI score, while Gheita et al. [22] and KPS
(unpublished) deﬁned it as biopsy-proven nephritis. The
meta-analysis showed that MMP-3 levels were signiﬁcantly
higher in the lupus nephritis group than in the nonnephritis
group (P = 0 003, Hedges’ g: 0.639, 95% CI 0.221-1.057)
(Table 2 and Figure 5).
In addition, subgroup meta-analysis involving two
studies [2, 18] was performed on patients with proteinuria
(n = 57) and those without (n = 82). Proteinuria was deﬁned
as >0.5 gm/24 hours according to the SLEDAI score. The
results revealed that serum MMP-3 levels were signiﬁcantly
higher in patients with overt proteinuria than in those with-
out (P = 0 028, Hedges’ g: 1.583, 95% CI 0.167-3.000)
(Table 2 and Figure 6).
3.5. Meta-analysis of MMP-3 Levels of SLE Patients with
Positive Anti-dsDNA Titer. Further meta-analyses were con-
ducted on SLE patients in subgroups based on abnormal
Model Study name Statistics for each study Hedges' g and 95% CI
Jin, 2013
Zhu., 2010
De Leeuw, 2006
Ribbens, 2002
Zucker, 1999
Ichikawa, 1998
Kotajima, 1998
Akiyama, 1997
Shingu, 1995
Zucker, 1994
Gheita, 2015
KPS (unpublished)
Fixed
Random
Hedges' g
Standard
error 
Lower
limit
Upper
limit Variance Z value P value
0.697 0.200 0.040 0.305 1.089 3.488 0.000
0.884 0.190 0.036 0.511 1.257 4.648 0.000
0.925 0.212 0.045 0.509 1.340 4.357 0.000
0.714 0.327 0.107 0.074 1.354 2.186 0.029
1.369 0.217 0.047 0.944 1.795 6.304 0.000
1.153 0.332 0.110 0.503 1.803 3.475 0.001
1.044 0.137 0.019 0.775 1.312 7.620 0.000
13.364 0.786 0.617 11.824 14.904 17.008 0.000
1.208 0.154 0.024 0.906 1.510 7.836 0.000
1.658 0.309 0.096 1.052 2.264 5.362 0.000
1.998 0.289 0.084 1.432 2.565 6.909 0.000
4.080 0.776 0.601 2.560 5.600 5.261 0.000
1.208 0.065 0.004 1.081 1.336 18.550 0.000
2.104 0.346 0.120 1.426 2.782 6.082 0.000
−4.00 −2.00 0.00 2.00 4.00
Decreasing MMP-3 Increasing MMP-3
Figure 2: Forest plot of random eﬀects meta-analysis of MMP-3 levels in SLE patients compared with healthy controls.
Model Study name Statistics for each study Hedges' g and 95% CI
Jin, 2013
Zhu., 2010
De Leeuw, 2006
Ribbens, 2002
Zucker, 1999
Ichikawa, 1998
Kotajima, 1998
Akiyama, 1997
Shingu, 1995
Zucker, 1994
Gheita, 2015
Fixed
Random
Hedges' g
Standard
error 
Lower
limit 
Upper
limit Variance Z value P value
0.697 0.200 0.040 0.305 1.089 3.488 0.000
0.884 0.190 0.036 0.511 1.257 4.648 0.000
0.925 0.212 0.045 0.509 1.340 4.357 0.000
0.714 0.327 0.107 0.074 1.354 2.186 0.029
1.369 0.217 0.047 0.944 1.795 6.304 0.000
1.153 0.332 0.110 0.503 1.803 3.475 0.001
1.044 0.137 0.019 0.775 1.312 7.620 0.000
13.364 0.786 0.617 11.824 14.904 17.008 0.000
1.208 0.154 0.024 0.906 1.510 7.836 0.000
1.658 0.309 0.096 1.052 2.264 5.362 0.000
1.998 0.289 0.084 1.432 2.565 6.909 0.000
1.188 0.065 0.004 1.060 1.316 18.172 0.000
1.963 0.351 0.123 1.276 2.650 5.598 0.000
−4.00 −2.00 0.00 2.00 4.00
Decreasing MMP-3 Increasing MMP-3
Figure 3: Forest plot of random eﬀects meta-analysis of MMP-3 levels in SLE patients compared with healthy controls (excluding pediatric
data from KPS).
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anti-double strand DNA antibody (anti-dsDNA Ab) titer
at the time of sample collection. The results involving
two studies—Kotajima et al. [2] and KPS (unpublished)—-
demonstrated no signiﬁcant diﬀerence in MMP-3 levels
between SLE patients with abnormally increased anti-
dsDNA Ab titer and those without (P = 0 898, Hedges’ g:
0.094, 95% CI -1.325-1.540) (Table 2 and Figure 7).
3.6. Assessment of Heterogeneity and Publication Bias. We
assessed statistical heterogeneity between the included stud-
ies (Table 2). In the meta-analysis of serum MMP-3 levels
comparing SLE patients with healthy controls and subgroup
analysis of proteinuria, the I2 test showed a value > 50%,
indicating substantial heterogeneity. Random eﬀects models
were used for meta-analyses. Although the funnel plot
showed symmetry (Figure 8), Egger’s regression analysis
indicated possibility of publication bias (Table 2).
4. Discussion
Due to a remitting-relapsing disease course of most patients
with SLE, biomarkers reﬂecting disease activity are desirable.
One of the candidate biomarkers is the MMP family.
MMP-3, also known as Stromelysin-1, degrades tissue
proteins including collagen types II, III, IV, IX, and X,
proteoglycans, ﬁbronectin, laminin, and elastin [12]. It can
also activate other MMPs, such as MMP-9, which is suggested
to be involved in the pathogenesis of SLE [13]. A recently pub-
lished meta-analysis involving 12 studies, however, showed
that circulating MMP-9 levels did not diﬀer between SLE
patients and healthy controls [23].
In this meta-analysis, serumMMP-3 levels were reviewed
in 662 SLE patients and 771 controls. There were 621 patients
and 762 controls extracted from 11 publications and 11
patients and 9 controls from a pediatric lupus cohort, KPS.
Model Study name Statistics for each study Hedges' g  and 95% CI
Ichikawa, 1998
KPS (unpublished)
Fixed
Random
Hedges' g
Standard
error 
Lower
limit 
Upper
limit Variance Z value P value
0.745 0.610 0.372 −0.450 1.940 1.222 0.222
−0.036 0.619 0.383 −1.250 1.177 −0.059 0.953
0.360 0.434 0.189 −0.491 1.212 0.829 0.407
0.360 0.434 0.189 −0.491 1.212 0.829 0.407
−4.00 −2.00 0.00 2.00 4.00
Decreasing MMP-3 Increasing MMP-3
Figure 4: Forest plot of random eﬀects meta-analysis of MMP-3 levels in SLE patients; male vs. female.
Model Study name Statistics for each study Hedges' g and 95% CI
Gheita, 2015
Kotajima, 1998
KPS (unpublished)
Fixed
Random
Hedges' g
Standard
error 
Lower
limit
Upper
limit Variance Z value P value
0.758 0.314 0.099 0.143 1.373 2.415 0.016
0.489 0.337 0.114 −0.172 1.150 1.449 0.147
0.678 0.572 0.327 −0.443 1.800 1.186 0.236
0.639 0.213 0.045 0.221 1.057 2.998 0.003
0.639 0.213 0.045 0.221 1.057 2.998 0.003
−4.00 −2.00 0.00 2.00 4.00
Decreasing MMP-3 Increasing MMP-3
Figure 5: Forest plot of random eﬀects meta-analysis of MMP-3 levels in SLE patients; with vs. without nephritis.
Model Study name Statistics for each study Hedges' g and 95% CI
Ichikawa, 1998
Kotajima, 1998
Fixed
Random
Hedges' g Standard Lower Upper 
error Variance limit limit Z value P value
2.333 0.587 0.345 1.182 3.483 3.974 0.000
0.960 0.195 0.038 0.578 1.342 4.925 0.000
1.096 0.185 0.034 0.734 1.459 5.927 0.000
1.535 0.677 0.459 0.207 2.862 2.266 0.023
−4.00 −2.00 0.00 2.00 4.00
Descreasing MMP-3 Inscreasing MMP-3
Figure 6: Forest plot of random eﬀects meta-analysis of MMP-3 levels in SLE patients; with vs. without proteinuria.
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The results showed ﬁrstly that serumMMP-3 levels were sig-
niﬁcantly higher in patients with SLE than in healthy controls
and secondly that serum MMP-3 levels were signiﬁcantly
elevated in patients with renal involvement than in those
without, both for active lupus nephritis and persistent pro-
teinuria. Previous studies suggested a correlation of serum
MMP-3 levels and hematologic indices, such as white blood
cells (WBC) and platelet counts [22]. However, in our
meta-analysis, subgroup comparisons were available only
for renal manifestations, sex, and serum anti-dsDNA anti-
body titer due to paucity of quantiﬁable data. Subgroup
comparison by sex and serum anti-dsDNA antibody titer
showed no signiﬁcant diﬀerence in the serum MMP-3 levels.
With regard to MMP-3, several studies have reported
elevation of circulatory MMP-3 levels in SLE patients
[2, 3, 12, 17, 22]. Our meta-analysis results were in agreement
with these studies. However, the correlation of serum
MMP-3 elevation and disease activity of SLE had been
inconsistent [2, 3, 12, 22]. Precisely, Kotajima et al.
reported that increased levels of serum MMP-3 in SLE
are related to clinical features relevant to lupus nephritis
[2]. They found that serum MMP-3 levels were signiﬁcantly
higher in SLE patients with active clinical presentation such
as persistent proteinuria, malar rash, and laboratory parame-
ters, such as cellular casts, anti-dsDNA antibodies, decreased
complement C3 and C4 levels, circulating immune com-
plexes, and hypoalbuminemia [2]. Similarly, Gheita et al.
found that serum levels of MMP-3 correlated with the sys-
temic lupus erythematosus disease activity index (SLEDAI)
and Systemic Lupus International Collaborating Clinics/-
damage index (SLICC/DI) scores [22]. However, Zucker
et al. found an increase in serum concentrations of MMP-3
in SLE but reported no correlation with disease activity
[12]. Moreover, Zhu et al. [3] reported that serum MMP-2,
MMP-3, and MMP-13 levels in SLE patients were signiﬁ-
cantly higher than those in controls but found no overall cor-
relation between serum levels of the three MMPs and disease
activity scores. Our data supported the relationship between
serumMMP-3 levels and renal involvement of SLE, implicat-
ing its correlation with disease activity. With regard to renal
involvement, a few studies investigated its association with
serum MMP levels. In a study by Gheita et al., the serum
MMP-3 levels correlated with class of lupus nephritis, show-
ing the highest levels in patients with class IV nephritis
[22]. Thiyagarajan et al. speculated in an animal study that
MMPs may represent some component of membrane
disintegration in progressive nephritis [24]. Our results
and previous works suggested that serum MMP-3 levels
may reﬂect the presence and possibly histological severity
of lupus nephritis in patients with SLE.
There are several limitations in this study. First, the mean
values of MMP-3 serum levels in SLE patients were relatively
high in those studies published in more remote years (before
the year 2000) and signiﬁcantly lower in those studies per-
formed after 2000. We speculate that diﬀerent ELISA kits
may have made a general comparability of results impossible.
This issue led to diﬀerent nonreproducible results in the past
(biomarker biology), but we have only included studies with
respective control cohorts and observed similar regulation in
most studies. Still, this is a major limitation in this study.
Second, this meta-analysis had small sample sizes, lowering
the power of the study. In those meta-analyses involving
two studies, the conclusions drawn may be subject to bias
because they are aﬀected by the small sample size of clinical
studies. In order to alleviate this, we used a random eﬀects
model in this study. However, we speculate that such a
limitation should raise attention and subsequently increase
publications in this subject. This is one of the reasons for
performing this work. Third, the data included in this
meta-analysis are extracted from heterogeneous groups.
The patients had diﬀerent demographics, such as age, sex,
and ethnicity, and varying clinical manifestations which
may have aﬀected the results. In particular, this meta-
analysis included data from one pediatric cohort (KPS) and
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Figure 8: Funnel plot of standard error in meta-analysis of MMP-3
levels in SLE patients compared with healthy controls.
Model Study name Statistics for each study Hedges' g and 95% CI
Kotajima, 1998
KPS (unpublished)
Fixed
Random
Hedges' g
Standard
error 
Lower
limit 
Upper
limit Variance Z value P value
0.739 0.192 0.037 0.364 1.115 3.857 0.000
−0.749 0.576 0.332 −1.879 0.380 −1.300 0.194
0.591 0.182 0.033 0.234 0.948 3.249 0.001
0.094 0.738 0.544 −1.352 1.540 0.128 0.898
−4.00 −2.00 0.00 2.00 4.00
Descreasing MMP-3 Inscreasing MMP-3
Figure 7: Forest plot of random eﬀects meta-analysis of MMP-3 levels in SLE patients; with vs. without increased anti-dsDNA titer.
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11 studies on adult patients which may have increased het-
erogeneity of the data. Lastly, there remains a possibility of
existing literature that was not accessible and the presence
of publication bias.
Although the results require cautious interpretation, we
speculate that this meta-analysis may provide some
evidence-based results regarding a controversial issue, based
on current publications. In the future, meta-analysis using
individual patient data and propensity scoring would make
a more powerful study.
Firstly, the results of the present study revealed that
serum MMP-3 levels were signiﬁcantly elevated in SLE
patients, which is in accordance with previous reports
[2, 3, 12, 22]. Secondly, the results showed that MMP-3
was signiﬁcantly elevated in patients with renal involvement,
both in histologically proven lupus nephritis and mere pro-
teinuria. Although the correlation of MMP-3 and lupus
activity requires further veriﬁcation, it is yet tempting to
speculate that elevated MMP-3 at initial diagnosis of SLE
may require more close follow-ups.
5. Conclusions
The present meta-analysis showed that serum MMP-3 levels
were signiﬁcantly higher in patients with SLE than in con-
trols and in patients with renal involvement than in those
without. Although our meta-analysis suggested that MMP-
3 likely correlate with disease activity, further studies in a
larger scale are warranted to elucidate the role of MMP-3 as
a putative biomarker of SLE.
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